An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2022-06-16
Target enrollment:
Participant gender:
Summary
This is an open-label Phase II modular study in patients with prostate cancer which will
assess safety, efficacy, and tolerability of AZD4635 in combination with other therapeutic
agents in different treatment arms (referred to as modules).
Combinations to be studied include: 1) Module 1: AZD4635 plus durvalumab; 2) Module 2:
AZD4635 plus oleclumab; 3) Module 3: AZD4635 plus durvalumab plus oleclumab.
The protocol may be amended to include other combinations.